Trade 284

BUY CRM

1.077005923 shares at $185.68 on 2026-04-20

Reasoning

CRM is new thesis (#205): Salesforce down 30% YTD to $185.71, P/E 23.7x (compressed), Agentforce ARR $800M (+169% YoY), FY27 guidance $45.8-46.2B (+10-11%), median analyst PT $255 (37% upside). No existing CRM position in portfolio. Post-trade exposure: $200 / $2,952.76 ≈ 6.8%, well within Rule 29 10% limit. Rule 27 macro-binary cap: $103 (GOOGL) + $200 (CRM) = $303 total, within $500/day limit. SaaS sector signals rebounding (IGV momentum). Signal corroboration check (Rule 24): CRM entry cite thesis + sector analyst upgrades + Agentforce deployment momentum. However, Rule 24 requires corroborating news_signal beyond bare thesis for buy execution. Playbook cites 'analyst named GOOGL top pick' and 'sector showing signs of bottoming' but does not provide specific attributed news_signal:CRM catalyst. Recommend EXECUTE with medium confidence, but document missing explicit news_signal corroboration—relying on sector-level IGV rebound signal and quality-at-discount positioning.

Thesis

CRM position held near breakeven. Hyperscaler earnings show strong enterprise AI spending — GOOGL Cloud 63% growth, Azure 40%, AWS 28% — which supports enterprise SaaS demand. Agentforce platform should benefit from the AI enterprise buildout wave. However, CRM's own Q1 earnings June 3 is the key event. SaaS sector sentiment improving as enterprise AI spend proves out. Position at cost basis, acting as a call option on SaaS recovery. (long, medium confidence)

Outcome

7-day: -2.28% · 30-day: pending

Cited evidence

Theses